The Chemours (CC) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BMO Capital | Maintained | Outperform | $18.00 from $26.00 | Aug 13, 2026 |
| JP Morgan | Maintained | Neutral | $15.00 from $22.00 | Aug 13, 2026 |
| UBS | Downgraded | Buy → Neutral | $18.00 from $29.00 | Aug 10, 2026 |
| Truist Securities | Maintained | Buy | $24.00 from $30.00 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $22.00 from $26.00 | Aug 6, 2026 |
| Mizuho | Maintained | Outperform | $25.00 from $30.00 | Jul 1, 2026 |
| JP Morgan | Maintained | Neutral | $22.00 from $17.00 | May 21, 2026 |
| RBC Capital | Maintained | Outperform | $29.00 from $26.00 | May 11, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $21.00 from $17.00 | May 11, 2026 |
| UBS | Maintained | Buy | $30.00 from $29.00 | May 8, 2026 |
| Truist Securities | Maintained | Buy | $30.00 from $27.00 | Apr 28, 2026 |
| Truist Securities | Maintained | Buy | $27.00 from $21.00 | Apr 9, 2026 |
| UBS | Maintained | Buy | $29.00 from $23.00 | Apr 9, 2026 |
| Mizuho | Maintained | Outperform | $21.00 from $17.00 | Mar 5, 2026 |
| Goldman Sachs | Maintained | Neutral | $18.00 from $14.00 | Feb 25, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $17.00 from $15.00 | Feb 23, 2026 |
| JP Morgan | Maintained | Neutral | $17.00 from $13.00 | Feb 23, 2026 |
| BMO Capital | Maintained | Outperform | $19.00 from $20.00 | Feb 23, 2026 |
| UBS | Maintained | Buy | $23.00 from $18.00 | Feb 23, 2026 |
| Truist Securities | Maintained | Buy | $21.00 from $18.00 | Jan 21, 2026 |
Frequently asked questions
What is the price target for CC stock?
The average 12-month analyst price target for The Chemours (CC) is $20.33, with a high estimate of $25.00 and a low of $15.00, across 6 analysts.
Is CC a buy, sell, or hold?
Analysts covering The Chemours currently average a Hold rating: 5 buy, 6 hold and 1 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CC?
The average price target of $20.33 implies 30.68% upside from the last price of $15.56.
What is the latest analyst rating on CC?
On Aug 13, 2026, BMO Capital maintained The Chemours at Outperform with a price target of $18.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.